265 related articles for article (PubMed ID: 25205367)
1. Place conditioning to apomorphine in rat models of Parkinson's disease: differences by dose and side-effect expression.
Campbell JC; Jeyamohan SB; De La Cruz P; Chen N; Shin D; Pilitsis JG
Behav Brain Res; 2014 Dec; 275():114-9. PubMed ID: 25205367
[TBL] [Abstract][Full Text] [Related]
2. Pramipexole- and methamphetamine-induced reward-mediated behavior in a rodent model of Parkinson's disease and controls.
Riddle JL; Rokosik SL; Napier TC
Behav Brain Res; 2012 Jul; 233(1):15-23. PubMed ID: 22727039
[TBL] [Abstract][Full Text] [Related]
3. The unilateral 6-OHDA rat model of Parkinson's disease revisited: an electromyographic and behavioural analysis.
Metz GA; Tse A; Ballermann M; Smith LK; Fouad K
Eur J Neurosci; 2005 Aug; 22(3):735-44. PubMed ID: 16101755
[TBL] [Abstract][Full Text] [Related]
4. Neuroprotective and neurotrophic effect of apomorphine in the striatal 6-OHDA-lesion rat model of Parkinson's disease.
Yuan H; Sarre S; Ebinger G; Michotte Y
Brain Res; 2004 Nov; 1026(1):95-107. PubMed ID: 15476701
[TBL] [Abstract][Full Text] [Related]
5. Performance of movement in hemiparkinsonian rats influences the modifications induced by dopamine agonists in striatal efferent dynorphinergic neurons.
Frau L; Morelli M; Simola N
Exp Neurol; 2013 Sep; 247():663-72. PubMed ID: 23499830
[TBL] [Abstract][Full Text] [Related]
6. Monoaminergic PET imaging and histopathological correlation in unilateral and bilateral 6-hydroxydopamine lesioned rat models of Parkinson's disease: a longitudinal in-vivo study.
Molinet-Dronda F; Gago B; Quiroga-Varela A; Juri C; Collantes M; Delgado M; Prieto E; Ecay M; Iglesias E; Marín C; Peñuelas I; Obeso JA
Neurobiol Dis; 2015 May; 77():165-72. PubMed ID: 25681534
[TBL] [Abstract][Full Text] [Related]
7. Differential behavioral reinforcement effects of dopamine receptor agonists in the rat with bilateral lesion of the posterior ventral tegmental area.
Ouachikh O; Dieb W; Durif F; Hafidi A
Behav Brain Res; 2013 Sep; 252():24-31. PubMed ID: 23727149
[TBL] [Abstract][Full Text] [Related]
8. GABAA-receptor activation in the subthalamic nucleus compensates behavioral asymmetries in the hemiparkinsonian rat.
Petri D; Pum M; Vesper J; Huston JP; Schnitzler A
Behav Brain Res; 2013 Sep; 252():58-67. PubMed ID: 23727148
[TBL] [Abstract][Full Text] [Related]
9. Histological, behavioural and neurochemical evaluation of medial forebrain bundle and striatal 6-OHDA lesions as rat models of Parkinson's disease.
Yuan H; Sarre S; Ebinger G; Michotte Y
J Neurosci Methods; 2005 May; 144(1):35-45. PubMed ID: 15848237
[TBL] [Abstract][Full Text] [Related]
10. Stress reduces the neuroprotective effect of exercise in a rat model for Parkinson's disease.
Howells FM; Russell VA; Mabandla MV; Kellaway LA
Behav Brain Res; 2005 Dec; 165(2):210-20. PubMed ID: 16159673
[TBL] [Abstract][Full Text] [Related]
11. Does contraversive circling in the 6-OHDA-lesioned rat indicate an ability to induce motor complications as well as therapeutic effects in Parkinson's disease?
Lane EL; Cheetham SC; Jenner P
Exp Neurol; 2006 Feb; 197(2):284-90. PubMed ID: 16005456
[TBL] [Abstract][Full Text] [Related]
12. Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson's disease in mice.
Iancu R; Mohapel P; Brundin P; Paul G
Behav Brain Res; 2005 Jul; 162(1):1-10. PubMed ID: 15922062
[TBL] [Abstract][Full Text] [Related]
13. Caffeine neuroprotective effects on 6-OHDA-lesioned rats are mediated by several factors, including pro-inflammatory cytokines and histone deacetylase inhibitions.
Machado-Filho JA; Correia AO; Montenegro AB; Nobre ME; Cerqueira GS; Neves KR; Naffah-Mazzacoratti Mda G; Cavalheiro EA; de Castro Brito GA; de Barros Viana GS
Behav Brain Res; 2014 May; 264():116-25. PubMed ID: 24525422
[TBL] [Abstract][Full Text] [Related]
14. Time-course gait analysis of hemiparkinsonian rats following 6-hydroxydopamine lesion.
Hsieh TH; Chen JJ; Chen LH; Chiang PT; Lee HY
Behav Brain Res; 2011 Sep; 222(1):1-9. PubMed ID: 21435355
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of behavioural effects of a selective NMDA NR1A/2B receptor antagonist in the unilateral 6-OHDA lesion rat model.
Warraich ST; Allbutt HN; Billing R; Radford J; Coster MJ; Kassiou M; Henderson JM
Brain Res Bull; 2009 Feb; 78(2-3):85-90. PubMed ID: 18822357
[TBL] [Abstract][Full Text] [Related]
16. Developing a preclinical model of Parkinson's disease: a study of behaviour in rats with graded 6-OHDA lesions.
Truong L; Allbutt H; Kassiou M; Henderson JM
Behav Brain Res; 2006 Apr; 169(1):1-9. PubMed ID: 16413939
[TBL] [Abstract][Full Text] [Related]
17. Behavioral differences in a rotenone-induced hemiparkinsonian rat model developed following intranigral or median forebrain bundle infusion.
Sindhu KM; Saravanan KS; Mohanakumar KP
Brain Res; 2005 Jul; 1051(1-2):25-34. PubMed ID: 15992782
[TBL] [Abstract][Full Text] [Related]
18. A potential target for the treatment of Parkinson's disease: effect of lateral habenula lesions.
Han B; Jin HJ; Song MY; Wang T; Zhao H
Parkinsonism Relat Disord; 2014 Nov; 20(11):1191-5. PubMed ID: 25219971
[TBL] [Abstract][Full Text] [Related]
19. The effects of unilateral 6-OHDA lesion in medial forebrain bundle on the motor, cognitive dysfunctions and vulnerability of different striatal interneuron types in rats.
Ma Y; Zhan M; OuYang L; Li Y; Chen S; Wu J; Chen J; Luo C; Lei W
Behav Brain Res; 2014 Jun; 266():37-45. PubMed ID: 24613235
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of D2/D3 receptors increases efficacy of ropinirole in chronically 6-OHDA-lesioned Parkinsonian rats.
Matsukawa N; Maki M; Yasuhara T; Hara K; Yu G; Xu L; Kim KM; Morgan JC; Sethi KD; Borlongan CV
Brain Res; 2007 Jul; 1160():113-23. PubMed ID: 17573046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
